动态对比增强超声分析在预测肝内胆管癌全身治疗早期反应中的应用
回顾性纳入24例经穿刺活检病理确诊的晚期(III/IV期)肝内胆管癌患者,于全身治疗前及治疗后2个月行肝脏对比增强超声、DCE-US分析、CT/MRI及血液检查,按1年m-RECIST结果分为反应组7例(19.2%)与非反应组17例(70.8%);反应组治疗后达峰时间延长、峰值强度降低,PE、WiR、WiPI、WoR显著下降(P<0.05),非反应组TIC显示治疗后增强更快,且PE与WiPI较反应组仅轻度下降(P<0.05)。
要点
- DCE-US定量参数可在全身治疗后2个月早期提示肝内胆管癌治疗反应。
- 反应组治疗后PE、WiR、WiPI、WoR显著下降(P<0.05)。
- 非反应组治疗后TIC显示增强更快,PE与WiPI较反应组轻度下降(P<0.05)。
核心结论
- DCE-US定量参数分析对肝内胆管癌患者全身治疗反应具有早期、定量评估的潜在价值。
研究设计与样本
- 回顾性研究,纳入24例经空芯针活检组织病理学确诊的晚期(第8版AJCC/UICC TNM分期III/IV期)肝内胆管癌患者,采用ACUSON Sequoia超声系统(Siemens Medical Solutions,德国)及5C1 MHz凸阵探头行肝脏CEUS,VueBox软件生成时间-强度曲线及定量参数,以CT/MRI为基础、按1年m-RECIST结果分为反应组与非反应组。
关键影像表现/征象
- 反应组治疗后达峰时间延长、TIC峰值强度降低。
- 非反应组TIC显示治疗后增强更快。
诊断标准与关键数值
- 以CT/MRI为基础、按1年m-RECIST结果分组:反应组7例(19.2%),非反应组17例(70.8%)。
- 反应组全身治疗2个月后PE、WiR、WiPI、WoR显著下降(P<0.05)。
- 非反应组治疗2个月后PE与WiPI较反应组轻度下降(P<0.05)。
临床应用与阅片要点
- 可参考DCE-US定量参数(PE、WiR、WiPI、WoR)及TIC形态变化,在全身治疗2个月时辅助判断肝内胆管癌治疗反应。
- 原文结论使用「has the potential value」,为潜在价值表述,尚未作为常规推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the value of dynamic contrast-enhanced ultrasound (DCE-US) analysis in early prediction of tumor response to systemic treatment in patients with intrahepatic cholangiocarcinoma (ICC).
PATIENTS & METHODS: In this retrospective study, patients diagnosed with ICC by core needle biopsy and histopathological results were included. All patients were diagnosed as advanced stages (stage III/IV) by the 8th edition of the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC) TNM staging system. Liver contrast-enhanced ultrasound (CEUS) examination, DCE-US analysis, CT/MRI, and blood tests were performed in all patients before and 2 months after systemic treatment. CEUS procedure was performed using an ultrasound system (ACUSON Sequoia; Siemens Medical Solutions, Germany) equipped with a 5C1 MHz convex array transducer. Time-intensity curves (TIC) and quantitative parameters were created with VueBox software. According to one-year results of the modified Response Evaluation Criteria in Solid Tumors (m-RECIST) based on CT/MRI, patients were divided into the responder group (RG) and the non-responder group (NRG). Before and 2 months after systemic therapy, the DCE-US perfusion parameters was compared using the paired-sample t test and the Wilcoxon test.
RESULTS: From September 2020 to December 2021, a total of 24 patients diagnosed with advanced ICC were included (11 males, 13 females, mean age 59.4 ± 1.8 years). According to the one year of m-RECIST results, 17 cases (70.8 %) were classified as non-responders by the final m-RECIST criteria, while 7 cases (19.2 %) were responders. Comparing before and 2 months after therapy, the RG took longer time to reach peak intensity, and the peak intensity of TIC was lower. While the TICs of NRG revealed faster enhancement after therapy. Among all DCE-US quantitative parameters, PE (peak enhancement), WiR (wash-in rate), WiPI (wash-in perfusion index) and WoR (wash-out rate) reduced significantly following 2 months of systemic therapy in RG (P < 0.05). Comparing to RG, PE and WiPI decreased slightly 2 months after therapy in NRG (P < 0.05).
CONCLUSIONS: The DCE-US analysis with quantitative parameters has the potential value to make early and quantitative evaluation of treatment response to systemic therapy in ICC patients.
引用
- Lu XY, Jiang J, Chen S, et al. Application of dynamic contrast enhanced ultrasound analysis in predicting early response to systemic therapy of intrahepatic cholangiocarcinoma. Eur J Radiol. 2024. PMID: 38547743. doi:10.1016/j.ejrad.2024.111439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。